Citation Impact
Citing Papers
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
2010 Standout
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
2015 StandoutNobel
Perifosine Inhibits Multiple Signaling Pathways in Glial Progenitors and Cooperates With Temozolomide to Arrest Cell Proliferation in Gliomas In vivo
2005
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
2010
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
2009 Standout
Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma
2010
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
2002
Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy
2004
Hallmarks of Cancer: The Next Generation
2011 Standout
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
2007
Salvage chemotherapy for oligodendroglioma
1996
Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma
2009
CDK inhibitors: positive and negative regulators of G1-phase progression
1999 Standout
Malignant Gliomas: MR Imaging Spectrum of Radiation Therapy- and Chemotherapy-induced Necrosis of the Brain after Treatment
2000
The p16INK4a/CDKN2A tumor suppressor and its relatives
1998
IDH1andIDH2Mutations in Gliomas
2009 Standout
Phase I Trial of Single-Dose Temozolomide and Continuous Administration of O6-Benzylguanine in Children with Brain Tumors: a Pediatric Brain Tumor Consortium Report
2007
An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma
2008
Exciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
2010
Immunosuppressive networks in the tumour environment and their therapeutic relevance
2005 Standout
Role for the p53 homologue p73 in E2F-1-induced apoptosis
2000 StandoutNatureNobel
Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy
2004
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas
2015
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma
2003
Procarbazine, lomustine, and vincristine (PCV) chemotherapy for Grade III and Grade IV oligoastrocytomas
1996
Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
1997
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
2006 Standout
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
2013
Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell‐mediated expansion
2004 StandoutNobel
Oligodendroglioma: An Appraisal of Recent Data Pertaining to Diagnosis and Treatment
1999
Glioblastoma and Other Malignant Gliomas
2013 Standout
Guillain-Barré syndrome
2016 Standout
Head and neck cancer
2008 Standout
Malignant astrocytic glioma: genetics, biology, and paths to treatment
2007 Standout
Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review
2011
Facets and determinants of quality of life in patients with recurrent high grade glioma
2005
GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME
2008
Antiangiogenic therapy in malignant gliomas
2008
Current Strategies in Whole-brain Radiation Therapy for Brain Metastases
2005
Human Cancer Cells Harbor T-Stumps, a Distinct Class of Extremely Short Telomeres
2007 StandoutNobel
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
2016 Standout
Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.
1994
Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy
1990 Standout
Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
2014 Standout
Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme
2005
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas
2003
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors
2002
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma
2005
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma1
2006
PCV Chemotherapy for Recurrent Oligodendrogliomas and Oligoastrocytomas
1998
p16(MTS-1/CDKN2/INK4a) in Cancer Progression
2001
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
2013 Standout
Malignant Gliomas in Adults
2008 Standout
Neuromuscular diseases associated with human immunodeficiency virus infection
1988
Delayed repletion of O6-methylguanine—DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity
2003
Dendritic Cell Therapy of High‐Grade Gliomas
2009
Overexpression of E2F‐1 in glioma triggers apoptosis and suppresses tumor growth in vitro and in vivo
1998
Sickle-cell disease
2010 Standout
Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology
2008
Management of brain metastases
2004
Current and future developments in the use of temozolomide for the treatment of brain tumours
2001
Prodrug activation enzymes in cancer gene therapy
2000
Primary brain tumours in adults
2003
Neuroblastoma
2007 Standout
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Primary brain tumours in adults
2012 Standout
Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases
2006 Standout
Correlation of molecular genetic analysis of P53 MDM2 P16 PTEN and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma
2003
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
2006
Immune Mechanisms in Inflammatory Polyneuropathya
1988
Antiangiogenic therapies for high-grade glioma
2009
Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances
2006
Polymyositis and dermatomyositis
2003 Standout
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
2009
Poly(ADP‐ribose) polymerase inhibitor increases growth inhibition and reduces G2/M cell accumulation induced by temozolomide in malignant glioma cells
2002
Diagnosis and Treatment of High-Grade Astrocytoma
2007
Novel anti-angiogenic therapies for malignant gliomas
2008
Brain Tumors
2001 Standout
Low-grade oligodendroglioma responds to chemotherapy
1996
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Newcastle Disease Virus Expressing a Dendritic Cell-Targeted HIV Gag Protein Induces a Potent Gag-Specific Immune Response in Mice
2010 StandoutNobel
Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists
1999 StandoutNobel
Phase II Study of Donepezil in Irradiated Brain Tumor Patients: Effect on Cognitive Function, Mood, and Quality of Life
2006
Mismatch Repair Deficiency Does Not Mediate Clinical Resistance to Temozolomide in Malignant Glioma
2008 StandoutNobel
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair–deficient malignant glioma xenograft
2005 StandoutNobel
Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas.
1999
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
2013 Standout
Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme
2005
Angiogenesis as a Therapeutic Target in Malignant Gliomas
2009
Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma
2003
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases
2016 Standout
Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males
2014
Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors
2004
Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low-Grade Oligodendroglioma or Oligoastrocytoma: Efficacy and Associations With Chromosomal Abnormalities
2003
Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme
2005
Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel.
1997
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site
2002
Direct evidence for the participation of gap junction-mediated intercellular communication in the transmission of damage signals from alpha -particle irradiated to nonirradiated cells
2001 Standout
Biology of Oligodendrocyte and Myelin in the Mammalian Central Nervous System
2001 Standout
Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.
2001
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
2007
Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class.
2000
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
2007
Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy
1998
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas
2003
Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma
2006
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
2003
Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy
2001
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
2007 Standout
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
2004
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
2002
Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971
2003
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
2010 Standout
How effective is BCNU in recurrent glioblastoma in the modern era?
2004
Role and Relevance of Neurocognitive Assessment in Clinical Trials of Patients With CNS Tumors
2006
Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
2001
Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
2003
Construction and Validation of Improved Triple Fusion Reporter Gene Vectors for Molecular Imaging of Living Subjects
2007 StandoutNobel
Works of Janet Bruner being referenced
Mutations of the p16 gene in gliomas.
1996
Assessment and Prognostic Significance of Mitotic Index Using the Mitosis Marker Phospho-histone H3 in Low and Intermediate-grade Infiltrating Astrocytomas
2006
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas
2002
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
2001
Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme
1995
Combination of 6-Thioguanine, Procarbazine, Lomustine, and Hydroxyurea for Patients with Recurrent Malignant Gliomas
1996
Combination of 6-Thioguanine, Procarbazine, Lomustine, and Hydroxyurea for Patients with Recurrent Malignant Gliomas
1996
The Treatment of Anaplastic Oligodendrogliomas and Mixed Gliomas
1993
Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells.
1996
Guillain-Barré syndrome with cytomegalovirus infection of peripheral nerves.
1985
Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse
1999